LKFT Stock — Lakefront Biotherapeutics: Cash, EV, Pipeline

What they do

We are a biotechnology company built to bring meaningful medicines to patients with serious diseases. We combine world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that drive value for patients and shareholders.

Source: 20-F FY2025 via SEC EDGAR

Share price

$33.45

Market cap

$2,204.3M

Cash

$98.9M

Enterprise value

$2,105.4M

Balance sheet

Cash	$98.9M
Debt	$0.0M
Net cash	$98.9M
Enterprise value	$2,105.4M
Basic shares	65.9M shares
Fully diluted shares	79.1M shares
Fully diluted market cap	$2,646.8M
Cash per share	$1.50

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

65.9M

Pre-funded warrants

0.0M

Options

13.2M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

79.1M

Cap table as of 2025-12-31.

Price history

Loading LKFT daily closes…

Loading price history…

Next catalyst

gamgertamig · Est. Nov 7, 2026 · guidance midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now guidance midpoint	gamgertamig gamgertamig Phase 1b in autoimmune diseases	Phase 1b	autoimmune diseases	2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GLPG3667

Stage not disclosed · Active

Target TYK2

Indications

Systemic lupus erythematosus (SLE) (Stage not disclosed)
Dermatomyositis (DM) (Stage not disclosed)

Status note Only product candidate disclosed in the filing; no phase, target or modality stated in excerpts. Company is winding down its cell therapy activities (no named cell therapy candidates disclosed) and is pursuing a business development strategy to acquire additional product candidates, in partnership discussions including Gilead.

Per-asset detail extracted from the 20-F filed 2026-03-26. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	3,785,991	no change	5.16%	2026-08-14
EcoR1 Capital	1,667,119	no change	2.48%	2026-08-14
DAFNA Capital	130,175	no change	0.74%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

LKFT — Lakefront Biotherapeutics ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

LKFT — Lakefront Biotherapeutics